EW - Edwards Lifesciences Corp Stock Price, Fair Value and News

85.08USD-0.76 (-0.89%)Market Closed

Market Summary

USD85.08-0.76

Market Closed

-0.89%

EW Alerts

1 major insider buys and 4 major insider sales recently.

EW Stock Price

View Fullscreen

EW RSI Chart

EW Valuation

Market Cap

51.3B

Price/Earnings (Trailing)

36.28

Price/Sales (Trailing)

8.35

EV/EBITDA

28.41

Price/Free Cashflow

188.91

EW Price/Sales (Trailing)

EW Profitability

EBT Margin

26.19%

Return on Equity

19.66%

Return on Assets

14.51%

Free Cashflow Yield

0.53%

EW Fundamentals

EW Revenue

Revenue (TTM)

6.1B

Rev. Growth (Yr)

9.5%

Rev. Growth (Qtr)

4.18%

EW Earnings

Earnings (TTM)

1.4B

Earnings Growth (Yr)

3.35%

Earnings Growth (Qtr)

-5.07%

Breaking Down EW Revenue

Last 7 days

0.9%

Last 30 days

-7.9%

Last 90 days

-0.8%

Trailing 12 Months

-4.1%

How does EW drawdown profile look like?

EW Financial Health

Current Ratio

3.75

Debt/Equity

0.08

Debt/Cashflow

0.88

EW Investor Care

Buy Backs (1Y)

0.60%

Diluted EPS (TTM)

2.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.1B	0	0	0
2023	5.5B	5.7B	5.8B	6.0B
2022	5.4B	5.4B	5.4B	5.4B
2021	4.5B	4.9B	5.1B	5.2B
2020	4.5B	4.3B	4.4B	4.4B
2019	3.8B	4.0B	4.2B	4.3B
2018	3.4B	3.5B	3.6B	3.7B
2017	3.1B	3.2B	3.3B	3.4B
2016	2.6B	2.7B	2.9B	3.0B
2015	2.4B	2.4B	2.4B	2.5B
2014	2.1B	2.1B	2.2B	2.3B
2013	1.9B	2.0B	2.0B	2.0B
2012	1.7B	1.8B	1.8B	1.9B
2011	1.5B	1.6B	1.6B	1.7B
2010	1.3B	1.4B	1.4B	1.4B
2009	1.3B	1.3B	1.3B	1.3B
2008	0	0	0	1.2B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Edwards Lifesciences Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	zovighian bernard j	bought	49,752	85.7421	580	ceo
May 06, 2024	lemercier jean-luc m	sold (taxes)	-22,079	85.25	-259	cvp, emeacla and japac
May 04, 2024	ullem scott b.	acquired	-	-	7,465	cvp, chief financial officer
May 04, 2024	lippis daniel j.	sold (taxes)	-24,807	85.25	-291	cvp, japac
May 04, 2024	lemercier jean-luc m	acquired	-	-	4,157	cvp, emeacla and japac
May 04, 2024	ullem scott b.	sold (taxes)	-377,743	85.25	-4,431	cvp, chief financial officer
May 04, 2024	chopra daveen	sold (taxes)	-197,865	85.25	-2,321	cvp, tmtt
May 04, 2024	bobo donald e jr	acquired	-	-	5,855	cvp,strategy/corp development
May 04, 2024	wood larry l	acquired	-	-	6,675	global president tavr & surg
May 04, 2024	wood larry l	sold (taxes)	-301,870	85.25	-3,541	global president tavr & surg

Which funds bought or sold EW recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	PANAGORA ASSET MANAGEMENT INC	unchanged	-	354,397	1,753,810	0.01%
May 07, 2024	O'Dell Group, LLC	sold off	-100	-33,855	-	-%
May 07, 2024	NorthRock Partners, LLC	added	5.36	321,065	1,323,220	0.11%
May 07, 2024	Bank Pictet & Cie (Europe) AG	unchanged	-	90,757	449,132	0.01%
May 07, 2024	Arizona State Retirement System	added	1.76	3,590,400	16,631,700	0.12%
May 07, 2024	SEI INVESTMENTS CO	added	162	97,513,400	140,064,000	0.20%
May 07, 2024	Smithfield Trust Co	added	1.49	19,000	86,000	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-12.75	7,397,000	86,495,000	0.11%
May 07, 2024	Strengthening Families & Communities, LLC	new	-	73,000	73,000	0.04%
May 07, 2024	MEEDER ASSET MANAGEMENT INC	new	-	14,716	14,716	-%

Are Funds Buying or Selling EW?

Are funds buying EW calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EW

No. of Funds

EW Alerts

1 major insider buys and 4 major insider sales recently.

Unveiling Edwards Lifesciences Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.63%	52,362,913	SC 13G/A
Jan 25, 2024	blackrock inc.	8.6%	52,171,889	SC 13G/A
Feb 09, 2023	vanguard group inc	8.34%	51,559,391	SC 13G/A
Feb 07, 2023	blackrock inc.	8.6%	53,060,508	SC 13G/A
Feb 09, 2022	vanguard group inc	7.86%	49,076,649	SC 13G/A
Feb 03, 2022	blackrock inc.	9.1%	57,040,983	SC 13G/A
Feb 10, 2021	vanguard group inc	7.76%	48,347,685	SC 13G/A
Jan 29, 2021	blackrock inc.	9.4%	58,596,560	SC 13G/A
Feb 12, 2020	vanguard group inc	7.79%	16,261,702	SC 13G/A
Feb 05, 2020	blackrock inc.	8.7%	18,200,799	SC 13G/A

Recent SEC filings of Edwards Lifesciences Corp

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 07, 2024	144	Notice of Insider Sale Intent
May 07, 2024	3	Insider Trading
May 07, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading

Peers (Alternatives to Edwards Lifesciences Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	169.3M	11.74%	12.93%	-5.51	2.5	7.49%	-244.90%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

Edwards Lifesciences Corp News

Latest updates

Edwards Lifesciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.2%	1,598	1,534	1,481	1,530	1,460	1,348	1,319	1,374	1,341	1,330	1,310	1,376	1,217	1,192	1,141	925	1,129	1,174	1,094	1,087	993
Gross Profit	3.0%	1,213	1,177	1,131	1,187	1,130	1,090	1,065	1,105	1,042	1,020	999	1,042	923	895	860	687	864	888	802	783	761
S&GA Expenses	2.0%	490	480	440	469	436	411	377	409	370	424	364	375	331	339	307	275	308	347	306	309	280
R&D Expenses	5.6%	285	270	270	270	261	232	234	251	229	233	238	225	207	196	196	182	187	194	196	192	171
EBITDA Margin	-1.0%	0.29*	0.29*	0.31*	0.31*	0.34*	0.36*	0.34*	0.34*	0.36*	0.35*	0.36*	0.36*	-	-	-	-	-	-	-	-	-
Interest Expenses	208.6%	17.00	-15.20	15.00	9.00	9.00	11.00	7.00	1.00	1.00	20.00	-0.80	-1.00	0.00	9.00	1.00	2.00	5.00	14.00	3.00	2.00	2.00
Income Taxes	12.3%	58.00	52.00	56.00	33.00	58.00	61.00	64.00	58.00	63.00	41.00	51.00	56.00	51.00	47.00	39.00	-46.30	54.00	35.00	27.00	29.00	28.00
Earnings Before Taxes	-2.9%	409	422	439	339	399	459	407	465	436	376	391	546	389	356	364	-168	365	316	302	271	278
EBT Margin	-1.6%	0.26*	0.27*	0.28*	0.28*	0.31*	0.33*	0.31*	0.31*	0.33*	0.33*	0.33*	0.34*	-	-	-	-	-	-	-	-	-
Net Income	-5.1%	352	371	385	306	341	398	344	406	374	335	340	490	338	310	325	-121	311	280	275	242	250
Net Income Margin	-1.5%	0.23*	0.23*	0.25*	0.25*	0.27*	0.28*	0.27*	0.27*	0.29*	0.29*	0.29*	0.30*	-	-	-	-	-	-	-	-	-
Free Cashflow	-346.0%	-118	48.00	356	-14.30	253	214	250	289	221	284	471	457	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.0%	9,736	9,363	9,371	9,004	8,651	8,293	8,638	8,425	8,420	8,503	8,160	7,662	7,214	7,237	6,801	6,424	6,076	6,488	5,966	5,574	5,469
Current Assets	3.3%	4,171	4,036	4,068	3,647	3,257	3,096	3,514	3,263	3,241	3,181	3,516	3,323	3,069	3,091	2,980	2,690	2,508	2,984	2,740	2,355	2,369
Cash Equivalents	7.0%	1,225	1,144	1,410	1,043	876	773	1,252	1,203	1,035	863	1,520	1,326	1,191	1,200	1,030	909	668	1,184	1,187	727	709
Inventory	3.3%	1,207	1,168	1,032	980	914	876	758	740	731	727	738	760	768	802	773	735	662	641	611	625	631
Net PPE	1.1%	1,768	1,749	1,681	1,662	1,646	1,633	1,566	1,560	1,552	1,547	1,465	1,446	1,418	1,395	1,276	1,196	1,101	1,060	974	931	892
Goodwill	-0.1%	1,253	1,254	1,297	1,300	1,308	1,164	1,159	1,164	1,166	1,168	1,170	1,172	1,171	1,173	1,170	1,168	1,166	1,168	1,157	1,174	1,103
Liabilities	-3.6%	2,550	2,644	2,644	2,558	2,589	2,486	2,420	2,482	2,575	2,667	2,619	-	-	2,663	-	-	-	-	-	-	-
Current Liabilities	-7.1%	1,111	1,195	1,239	1,157	1,082	1,022	918	969	950	1,032	967	886	799	894	846	873	747	902	776	697	647
Long Term Debt	0.0%	597	597	597	597	597	596	596	596	596	596	596	595	595	595	595	595	595	594	594	594	594
LT Debt, Non Current	0.0%	597	597	597	597	597	596	596	596	596	596	596	595	595	595	595	595	595	594	594	594	594
Shareholder's Equity	7.0%	7,118	6,650	6,658	6,447	6,062	5,807	6,218	5,944	5,845	5,836	5,541	5,133	4,658	4,574	4,210	3,839	3,901	4,148	3,815	3,500	3,448
Retained Earnings	3.9%	9,344	8,992	8,623	8,238	7,931	7,590	7,192	6,848	6,442	6,068	5,733	5,393	4,903	4,565	4,256	3,930	4,052	3,742	3,461	3,187	2,944
Additional Paid-In Capital	4.6%	2,380	2,274	2,211	2,146	2,049	1,969	1,915	1,853	1,769	1,700	1,643	1,579	1,497	1,438	1,382	1,324	1,676	1,623	1,570	1,512	1,449
Accumulated Depreciation	-100.0%	-	857	-	-	-	750	-	-	-	655	-	-	-	599	-	-	-	512	-	-	-
Shares Outstanding	0.2%	602	601	607	608	608	608	620	622	622	623	624	623	-	-	-	-	-	-	-	-	-
Minority Interest	-1.3%	69.00	69.00	70.00	71.00	84.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	56,850	-	-	-	58,454	-	-	-	64,028	-	-	-	42,641	-	-	-	34,109	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-139.2%	-53.50	137	412	34.00	314	283	310	332	293	374	532	526	301	400	216	231	207	403	437	341	2.00
Share Based Compensation	46.2%	45.00	31.00	33.00	37.00	39.00	28.00	30.00	36.00	32.00	24.00	27.00	30.00	28.00	21.00	23.00	25.00	24.00	18.00	20.00	22.00	21.00
Cashflow From Investing	347.5%	63.00	14.00	89.00	70.00	1.00	95.00	-201	130	230	-965	-377	-329	-49.70	-259	-126	-10.20	-134	-445	-12.70	-88.30	-49.50
Cashflow From Financing	114.9%	62.00	-413	-143	52.00	-206	-838	-69.90	-308	-368	-62.00	39.00	-59.00	-274	41.00	34.00	24.00	-586	37.00	34.00	-231	44.00
Buy Backs	-100.0%	0.00	448	174	8.00	249	866	100	355	406	97.00	2.00	112	303	0.00	1.00	9.00	615	-	1.00	256	6.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EW Income Statement

2024-03-31

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 1,598.2	$ 1,459.6
Cost of sales	385.6	329.5
Gross profit	1,212.6	1,130.1
Selling, general, and administrative expenses	489.7	436.3
Research and development expenses	285.2	261.2
Intellectual property agreement and certain litigation expenses (Note 3)	8.9	43.5
Change in fair value of contingent consideration liabilities (Note 7)	0.0	0.7
Separation costs (Note 4)	41.3	0.0
Operating income, net	387.5	388.4
Interest income, net	(16.5)	(8.6)
Other income, net	(5.4)	(1.6)
Income before provision for income taxes	409.4	398.6
Provision for income taxes	58.4	58.1
Net income	351.0	340.5
Net loss attributable to noncontrolling interest	(0.9)	0.0
Net income attributable to Edwards Lifesciences Corporation	$ 351.9	$ 340.5
Earnings per share:
Basic (in dollars per share)	$ 0.58	$ 0.56
Diluted (in dollars per share)	$ 0.58	$ 0.56
Weighted-average number of common shares outstanding:
Basic (in shares)	601.6	607.5
Diluted (in shares)	604.1	610.9

EW Balance Sheet

2024-03-31

CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 1,224.6	$ 1,144.0
Short-term investments (Note 5)	473.0	500.5
Accounts receivable, net of allowances of $13.5 and $8.3, respectively	817.6	775.1
Other receivables	59.3	61.8
Inventories (Note 2)	1,207.3	1,168.2
Prepaid expenses	138.1	146.8
Other current assets	250.6	239.3
Total current assets	4,170.5	4,035.7
Long-term investments (Note 5)	455.6	583.9
Property, plant, and equipment, net	1,767.9	1,749.4
Operating lease right-of-use assets	98.4	94.0
Goodwill	1,252.8	1,253.5
Other intangible assets, net	446.8	428.4
Deferred income taxes	776.7	754.6
Other assets (Note 2)	767.6	463.7
Total assets	9,736.3	9,363.2
Current liabilities
Accounts payable	212.3	201.4
Accrued and other liabilities (Note 2)	873.7	969.1
Operating lease liabilities	24.8	24.9
Total current liabilities	1,110.8	1,195.4
Long-term debt	597.2	597.0
Taxes payable	79.6	80.6
Operating lease liabilities	77.2	73.0
Uncertain tax positions	336.6	339.3
Litigation settlement accrual	82.0	94.2
Other liabilities	266.5	264.3
Total liabilities	2,549.9	2,643.8
Commitments and contingencies (Note 11)
Stockholders' equity
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding	0.0	0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 651.8 and 650.5 shares issued, and 602.4 and 601.1 shares outstanding, respectively	651.8	650.5
Additional paid-in capital	2,379.8	2,274.4
Retained earnings	9,344.3	8,992.4
Accumulated other comprehensive loss (Note 12)	(233.3)	(242.8)
Treasury stock, at cost, 49.4 and 49.4 shares, respectively	(5,024.7)	(5,024.5)
Total Edwards Lifesciences Corporation stockholders' equity	7,117.9	6,650.0
Noncontrolling interest	68.5	69.4
Total stockholders' equity	7,186.4	6,719.4
Total liabilities and equity	$ 9,736.3	$ 9,363.2

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

CEO	Mr. Bernard J. Zovighian
WEBSITE	edwards.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	17300

Edwards Lifesciences Corp Frequently Asked Questions

What is the ticker symbol for Edwards Lifesciences Corp? What does EW stand for in stocks?

EW is the stock ticker symbol of Edwards Lifesciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Edwards Lifesciences Corp (EW)?

As of Wed May 08 2024, market cap of Edwards Lifesciences Corp is 51.27 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EW stock?

You can check EW's fair value in chart for subscribers.

What is the fair value of EW stock?

You can check EW's fair value in chart for subscribers. The fair value of Edwards Lifesciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Edwards Lifesciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EW so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Edwards Lifesciences Corp a good stock to buy?

The fair value guage provides a quick view whether EW is over valued or under valued. Whether Edwards Lifesciences Corp is cheap or expensive depends on the assumptions which impact Edwards Lifesciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EW.

What is Edwards Lifesciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, EW's PE ratio (Price to Earnings) is 36.28 and Price to Sales (PS) ratio is 8.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EW PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Edwards Lifesciences Corp's stock?

In the past 10 years, Edwards Lifesciences Corp has provided 0.335 (multiply by 100 for percentage) rate of return.